MRNA — Moderna, Inc.

Summary of Moderna's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q3 2025 revenue totaled $1 billion, a 45% year-over-year decline, primarily due to lower COVID vaccine demand. Year-to-date revenue is approximately $1.3 billion.
• Net Loss: The company reported a net loss of $200 million, compared to a net income of $13 million in Q3 2024. Loss per share was $0.51.
• Cash Position: Moderna ended the quarter with $6.6 billion in cash and investments, down from $7.5 billion in Q2 2025.
• Cost Management: Achieved a 34% reduction in combined costs (cost of sales, R&D, SG&A) compared to Q3 2024, with significant improvements in manufacturing efficiency.

2. Strategic Updates and Business Highlights

• Product Approvals:
  • Spikevax and mNEXSPIKE (new COVID vaccine) received approvals for the 2025-2026 strain in multiple countries.
  • mRESVIA (RSV vaccine) is now approved in 40 countries.
• Partnerships: Established manufacturing facilities in Canada, the U.K., and Australia, with multiyear offtake agreements, and successfully delivered the first Canadian-made mRNA vaccines.
• Pipeline Progress: Positive Phase III flu efficacy data for mRNA-1010 and mRNA-1083 (flu plus COVID combination). However, the CMV vaccine program was discontinued after failing to meet primary efficacy endpoints.

3. Forward Guidance and Outlook

• Revenue Guidance: Narrowed full-year revenue guidance to $1.6 billion to $2 billion, down from $1.5 billion to $2.2 billion. U.S. revenue is expected to be $1 billion to $1.3 billion, reflecting a 15% to 33% decline year-over-year.
• Cost Reductions: Projected cash costs for 2025 are lowered to $4.6 billion, with a goal of achieving cash breakeven by 2028.
• Future Milestones: Anticipated approvals for the flu and combination vaccines, and continued progress in oncology and rare disease programs.

4. Bad News, Challenges, or Points of Concern

• Declining COVID Vaccine Demand: The significant drop in vaccination rates is a major concern, with Q3 U.S. vaccinations down approximately 30% year-over-year.
• CMV Vaccine Setback: The failure of the CMV vaccine to meet efficacy endpoints raises questions about the viability of similar programs targeting latent viruses.
• Revenue Uncertainty: The reliance on COVID vaccine sales, which are expected to decline, poses risks to future revenue growth.

5. Notable Q&A Insights

• Cost Management Strategy: Management emphasized that cost reductions are driven by efficiency improvements rather than deprioritizing key investments. They continue to focus on optimizing R&D expenditures.
• Pipeline Evaluation: There is a cautious approach to new investments in R&D until breakeven targets are met, with a focus on maximizing cash efficiency.
• Market Dynamics: The company is actively monitoring vaccination rates and adjusting forecasts accordingly, with a strong emphasis on maintaining market share for mNEXSPIKE.
• Future Collaborations: Discussions with pharmaceutical partners are ongoing to fund further developments, particularly in the area of latent vaccines.

Overall, while Moderna has made significant strides in cost management and product approvals, challenges related to declining COVID vaccine demand and setbacks in the CMV program present notable risks to its future growth trajectory.